Wecare Probiotics is Asia's No.1 Bacillus coagulans manufacturer with 200T annual BC99 capacity (>90% China market share). 300B CFU/g, 150°C heat resistance, 10+ clinical trials, FDA GRAS. Trusted CDMO for global brands.

The world has revolutionized obesity and Type 2 diabetes treatment with GLP-1 receptor agonists (GLP-1RAs). Yet, prolonged monotherapy often leads to waning efficacy. Scientists have uncovered a breakthrough: modulating the gut microbiome to avert this plateau and amplify metabolic recovery.

We will attend Natural Products Expo West 2026 at Anaheim Convention Center (Mar 4-6), Booth 3717, showcasing our flagship strain BC99 with over 100°C heat resistance

WECARE International Probiotics & Health Conference 2026 will be held in Suzhou on March 20, focusing on probiotics and sports nutrition, with registration now open for global peers.

A specific probiotic strain, Akk11, may be reshaping the therapeutic paradigm for Parkinson’s disease (PD). Two recent high-impact studies from Wecare Research Institute show that this strain not only mitigates PD-related constipation but also ameliorates depressive phenotypes—two frequently comorbid, clinically intractable non-motor symptoms (NMS).

Parkinson's disease (PD) is not just a movement disorder; it also involves significant non-motor symptoms, particularly constipation and depression. These symptoms, which affect a large portion of patients, are closely tied to dysfunction in the gut-brain axis. Constipation is present in up to 70% of PD patients, while depression is also highly prevalent.